reason report
bottom line rais near mid-term revenu
forecast increas price target alexion
follow yesterday result manag
commentari expect core controversi regard brand
biosimilar competit threat soliri persist immedi futur
begin dissip later year compani bridg away
core product increasingli confid compani
abil diversifi away biosimilar risk on-going upcom
product launch value-enhanc line extens broaden
pipelin stock benefit continu strong perform
exist product year multipl catalyst around
mani new indic emerg rare diseas medicin final
backstop investor see attract larg acquisit
alexion compani small footprint long tail portfolio
would natur add-on global compani look near-term
growth long-term cash flow compani recent move
new indic new formul new product make
attract target
yesterday alexion report financi result exceed
street expect top bottom line issu
posit product revenu earn guidanc soliri
product sale vs con drove revenu ep beat
compani guid soliris/ultomiri revenu
recent consensu low-end guidanc rang
investor recogn guidanc reflect cautiou worst-cas
outlook compani compani benefit
steadi quarterli consensu surpris compani indic
on-going launch myasthenia gravi mg continu strong
estim mg alreadi account soliri sale
us mg track becom largest soliri indic us
later year meanwhil ultomiri launch paroxysm nocturn
hemoglobinuria pnh addit upcom approv soliri
ultomiri maintain posit momentum alexion
earlier pipelin begin report proof concept data come
month alexion earli commentari ultomiri launch suggest
virtual new start pnh alreadi ultomiri
signific switch establish patient alreadi occur
acceler reimburs polici establish
new launch poc studi defin outlook alexion
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
success rebuilt pipelin sever small mid-siz
busi develop transact past two year
begin report mid-stag data enter pivot trial soon first
proof concept data one new pipelin addit come
first half rare autoimmun hemolyt
anemia second half focu return launch
ultomiri pnh soliriss launch mg eu nmo
alexion activ bd past month
also execut expans current complement franchis
neurolog offer compel product valu proposit
legaci pnh ahu indic compani pnh ahu
offer soon consist two market product two activ
subcutan sc formul program pose dens
barrier entri brand biosimilar competitor
increasingli confid ultomiri convers new
formul protect alexion core franchis brand
gener competit thu enabl revenu growth late
updat compani model includ separ
soliri ultomiri revenu forecast model
convers pnh ahu patient ultomiri major market
addit increas peak revenu opportun
myasthenia gravi base current launch trajectori increas
probabl success neuromyel optica nmo base
posit phase data updat price target
maintain outperform rate ahead catalyst rich
previous cover highlight alexion
confer call recap note link
price target rate stock
outperform alexion lead compani develop commerci treatment
complement mediat diseas histor greater alexion revenu come
two rare diseas indic soliri recent approv soliri myasthenia
gravi upcom label expans on-going launch ultomiri alexion final
diversifi portfolio beyond soliri two core ahu pnh indic believ
alexion increas revenu complement franchis competit
threat soliri overst view given long safeti efficaci histori soliri
well alexion progress develop improv version ultomiri greater
potenc longer half-lif conveni dose beyond complement kanuma strensiq
continu grow steadili still believ two product could combin contribut
expect oper margin maintain
futur find alexion well posit grow ep doubl digit next five
top-lin driven soliri demand
alexion report total revenu beat consensu expect
driven strong soliri volum growth top-lin beat driven y/i volum
growth alexion product includ price headwind total soliri product sale
grew y/i higher consensu forecast continu
strength myasthenia gravi mg launch evid calcul mg sale
quarter us soliri sale strensiq sale
increas q/q y/i fell short consensu kanuma sale
grow y/i volum growth line consensu estim
ep came ahead base top-lin
total non-gaap expens line consensu expect non-gaap
less consensu expect less estim non-gaap
sg ahead consensu ahead estim alexion
oper margin quarter
alexion tax rate dilut share count period flat
million result pro forma dilut ep beat consensu
full-year guidanc appear solid view
alexion current manag team previous guid conserv vs prevail consensu
ultim exceed origin consensu guidanc context alexion
initi guidanc appear quit posit would expect compani
exceed guidanc current street expect alexion guid total revenu
y/i compar recent consensu soliris/ultomiri guidanc
y/i recent consensu strensiq/kanuma guidanc
indic y/i growth well consensu expect
manag commentari suggest price headwind includ
guidanc strensiq proactiv discount order improv access
us alexion expect expens ratio sg expens ratio
result oper margin higher consensu
compani expect effect tax rate dilut ep
current forecast street manag guidanc suggest y/i ep
growth non-gaap basi
break ultomiri forecast show biosimilar threat overst
broken soliri ultomiri forecast within compani model market model
variou indic first time updat model assum slight lower rate
switch soliri ultomiri manag guidanc taken care effort
model biosimilar entri soliri appropri time overal continu believ
alexion complement franchis grow double-digit percentag point annual
growth moder mid-low singl digit thereaft believ layer
mg nmo launch soliri off-set near-term eros core
ahu pnh franchis ultomiri increas overal number
patient one alexion antibodi longer term forecast soliri growth stabil
declin slowli biosimilar product enter market variou indic
geographi differ stage initi biosimilar entri europ continu
forecast moder growth ultomiri
base assumpt underli revis forecast convers us pnh
us ahu patient ultomiri alexion guidanc suggest convers
indic end pnh ahu us germani japan
outsid us forecast convers rate ultomiri within two year launch
indic longer term expect convers pnh ahu patient
ultomiri major market assum patient switch remain
ultomiri follow stage entri biosimilar eculizumab forecast revenu
ultomiri grow
soliri forecast continu double-digit percentag growth prior full impact
pnh ahu launch ultomiri earli biosimilar entri begin
europ earli forecast soliri return modest low-single-digit growth
non-eu market neurolog launch matur core indic becom lesser
compon revenu base estim us ex-u
soliri sale core pnh ahu indic greater major come
mg nmo transit estim alexion total sale
would at-risk biosimilar entrant prior eu pnh exposur
would approxim doubl orphan drug exclus ahu expir
eu assum approxim soliri use eu pnh suggest
total compani revenu would risk biosimilar exhibit
highli unlik scenario exist pnh patient ultomiri would requir convert
biosimilar eculizumab total at-risk number increas total sale
believ addit biosimilar could enter market
europ us row market japan issu composit matter
patent us japan expir begin forecast moder eros soliri
brand us rapid eros geographi
total forecast alexion complement franchis grow
prior biosimilar entri assum first biosimilar eculizumab may
approv model declin low-single-digit growth franchis forecast
peak exhibit
exhibit alexion sale risk biosimilar prior
total
exhibit updat revenu forecast drug geographi
clinic regulatori commerci catalyst
recent year entir focu alexion pipelin ultomiri core
pnh ahu indic clearli chang alexion busi develop
strategi past month result divers pipelin spread across early/mid/l
stage develop view alexion attract catalyst pathway start
regulatori progress launch soliri ultomiri new indic alexion recent
file sbla soliri nmo indic expect full approv occur us
ultomiri expect approv europ japan pnh later year well
regulatori file ahu mid-year term clinic readout alexion disclos top-
line phase ii data warm autoimmun hemolyt anemia waiha
pemphigu first half result could potenti valid compani
syntimmun acquisit encourag investor consid opportun
model ahead pivot trial initi indic later year addit alexion
plan initi new pivot trial ultomiri myasthenia gravi nmo proof
concept studi amyotroph later sclerosi al primari progress multipl sclerosi
ppm later year term life-cycle manag alexion enrol subject pivot
bridg studi weekli subcutan ultomiri also begin phase ii trial
subcutan later
durabl revenu earn lift pt maintain op
base recent quarter made extens revis revenu forecast
compani model result price target increas major
chang revenu forecast break-out soliri ultomiri forecast
indic indic basi strong launch soliri mg compel phase data
nmo encourag us increas forecast mg rais probabl success
nmo revis soliris/ultomiri revenu forecast increas
second major chang reduc peak revenu forecast
strensiq base manag guidanc price commentari reduc
long-term revenu forecast strensiq much later year forecast
estim peak sale kanuma increas forecast later year
double-digit percentag howev remain minor portion alexion portfolio total
revenu forecast increas remain consensu
term oper expens reduc forecast increas
total opex sg low mid-singl digit percentag point near-mid
term forecast oper margin long-term stabil
rang non-gaap dilut ep estim increas futur year
remain significantli recent consensu although street estim
like increas base manag guidanc base chang
revis price target increas maintain outperform rate alexion
price target base simpl averag three
approach believ reason basi valu stock today approach
simpl price earn multipl compar large-cap biopharma compani
discount cash flow dcf use rel multipl similar growth compani
ep appli ep estim alexion give fair valu
stock use expect ep compound-annual-growth-rate alexion period appli
current averag ratio larg molecul large-cap biotech compani give ep
multipl discount multipl compress alexion
appli ep estim give fair valu final dcf use termin
growth rate post give current valu averag three valuat
methodolog pt
risk view outlook valuat alexion includ major chang price
reimburs coverag label soliri compani main product today risk
includ commerci develop disappoint recent launch product strensiq
kanuma well develop disappoint addit indic soliri
successor complement inhibitor product final brand gener competitor
product soliri come market captur greater share caus greater market price
disrupt current expect futur outlook valuat would undermin
opportun better perform valu expect includ stronger initi
adopt recent launch new product forecast success develop
commerci new indic soliri beyond neuromyel optica
myasthenia gravi novel rare diseas medicin time horizon forecast
sale non-gaap
share count period dilut
guidanc
svb leerink compani file zack factset consensu
svb leerink compani file zack factset consensu
million
svb leerink llc research compani file
million
good sold
 total revenu
sg total revenu
svb leerink llc research compani file
brand
type event
event trial detail
date known
up/down
leerink view
combin waiha pv ph data
present
combin waiha pv ph data
present
sound like patient clinic poc studi
biomark endpoint prelud larger pivot
bridg trial pnh indic
svb leerink llc research compani file
analysi stock price svb leerink target alexion
method today larg cap brand biopharma futur ep multipl ep
svb leerink estimate earn
current averag larg cap biopharma multipl ep
svb leerink adjust ep estim
capit
number period
impli target price
method leerink intrins valu base dcf current product net
current svb leerink dcf marketed/l stage program
current estim valu asset
method project forward earn multipl ep base ep
compound-annual-growth-rate larg cap biotech ratio
averag growth larg cap biopharma co celg
impli ep multipl discount vs full growth-adj multipl
averag method
svb leerink llc research compani file factset
